Effect of Clopidogrel With and Without Eptifibatide on Tumor Necrosis Factor-Alpha and C-Reactive Protein Release After Elective Stenting: Results From the CLEAR PLATELETS 1b Study Original Research Article

Objectives This study was performed to compare the effects of antiplatelet regimens on early inflammation and cardiac marker release after elective stenting. Background Few data exist regarding the comparative effects of specific antiplatelet regimens on early inflammation marker release after stenting. Methods In a 2 × 2 factorial randomized investigation, patients undergoing stenting were treated with either clopidogrel alone (300 mg or 600 mg; n = 60) or clopidogrel with eptifibatide (n = 60). Platelet aggregation (5 and 20 μM adenosine diphosphate [ADP]), ADP-stimulated expression of active glycoprotein (GP) IIb/IIIa, and platelet-bound P-selectin, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), and cardiac markers were measured. Results Compared with a strategy of clopidogrel alone, clopidogrel + eptifibatide reduced the release of cardiac markers. A marked reduction in platelet aggregation and active GP IIb/IIIa expression (p ≤ 0.001) with clopidogrel + eptifibatide was associated with a decrease in CRP and TNF-α release (p ≤ 0.001). Conclusions A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone. The mechanistic and clinical implications of attenuated periprocedural inflammation and myocardial necrosis with a strategy of GP IIb/IIIa inhibition warrant further investigation.